Tudor Investment Corp ET AL Has $411,000 Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)

Tudor Investment Corp ET AL decreased its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 49.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,575 shares of the company's stock after selling 16,242 shares during the period. Tudor Investment Corp ET AL's holdings in Beam Therapeutics were worth $411,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. GAMMA Investing LLC increased its holdings in shares of Beam Therapeutics by 23.9% in the fourth quarter. GAMMA Investing LLC now owns 5,722 shares of the company's stock valued at $142,000 after buying an additional 1,102 shares in the last quarter. Avanza Fonder AB acquired a new stake in Beam Therapeutics during the 4th quarter valued at $1,247,000. SG Americas Securities LLC raised its stake in Beam Therapeutics by 19.4% during the 4th quarter. SG Americas Securities LLC now owns 12,118 shares of the company's stock valued at $301,000 after purchasing an additional 1,971 shares during the period. Blue Trust Inc. lifted its position in shares of Beam Therapeutics by 36.3% in the fourth quarter. Blue Trust Inc. now owns 4,274 shares of the company's stock worth $105,000 after purchasing an additional 1,139 shares in the last quarter. Finally, KBC Group NV lifted its position in shares of Beam Therapeutics by 103.2% in the fourth quarter. KBC Group NV now owns 4,143 shares of the company's stock worth $103,000 after purchasing an additional 2,104 shares in the last quarter. Institutional investors own 99.68% of the company's stock.

Insider Activity

In other news, insider Christine Bellon sold 5,674 shares of the stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total transaction of $104,117.90. Following the completion of the transaction, the insider now directly owns 117,294 shares in the company, valued at $2,152,344.90. This represents a 4.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO John M. Evans sold 30,663 shares of the stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $18.35, for a total transaction of $562,666.05. Following the transaction, the chief executive officer now owns 986,249 shares of the company's stock, valued at approximately $18,097,669.15. This represents a 3.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 43,771 shares of company stock valued at $803,198 in the last quarter. Company insiders own 4.20% of the company's stock.

Beam Therapeutics Stock Down 1.0%

BEAM stock traded down $0.19 during trading on Tuesday, hitting $18.05. The company had a trading volume of 1,718,364 shares, compared to its average volume of 2,023,015. The firm has a 50-day moving average price of $19.92 and a 200-day moving average price of $24.33. Beam Therapeutics Inc. has a 12 month low of $13.52 and a 12 month high of $35.25. The stock has a market cap of $1.82 billion, a price-to-earnings ratio of -10.26 and a beta of 2.35.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.13). The business had revenue of $7.47 million for the quarter, compared to the consensus estimate of $14.69 million. Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The business's revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.21) EPS. Equities analysts expect that Beam Therapeutics Inc. will post -4.57 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on BEAM shares. Bank of America raised shares of Beam Therapeutics from a "neutral" rating to a "buy" rating and set a $42.00 price target on the stock in a research note on Friday, March 28th. Wedbush reaffirmed an "outperform" rating and issued a $57.00 price target on shares of Beam Therapeutics in a research note on Monday, March 10th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Beam Therapeutics in a research note on Wednesday, March 12th. Scotiabank raised shares of Beam Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $40.00 price target on the stock in a research note on Monday, March 10th. Finally, Barclays decreased their price objective on shares of Beam Therapeutics from $31.00 to $25.00 and set an "equal weight" rating for the company in a report on Wednesday, May 7th. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $48.75.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.